This inventor holds 1 USPTO granted patent. Top assignee: Catalyst Therapeutics Pty Ltd.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Chris Burns: Innovator in Bromodomain Inhibition
Introduction
Chris Burns is an accomplished inventor based in Victoria, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic potential.
Latest Patents
Chris Burns holds a patent for "Benzodiazepines as bromodomain inhibitors." This invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts, or prodrugs thereof. These compounds have potential as bromodomain (BRD) inhibitors, showcasing his innovative approach to drug development.
Career Highlights
Chris is associated with Catalyst Therapeutics Pty Ltd., where he continues to advance his research and development efforts. His work focuses on creating effective therapeutic agents that can address various medical conditions.
Collaborations
Throughout his career, Chris has collaborated with notable professionals in the field, including Jean-Marc Garnier and Phillip Patrick Sharp. These partnerships have enhanced his research and contributed to the advancement of his projects.
Conclusion
Chris Burns exemplifies the spirit of innovation in the pharmaceutical industry, with his work on bromodomain inhibitors paving the way for future advancements in therapeutic treatments. His contributions are a testament to the importance of research and collaboration in the field of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile